Galmed Pharmaceuticals Ltd. filings document the company’s foreign private issuer reporting, Aramchol development disclosures and public-company governance matters. Recent Form 6-K reports furnish press releases on Aramchol-based collaborations, brain-penetrating formulation work, scientific presentations, Nasdaq minimum bid price correspondence and shareholder meeting materials.
The filing record also includes proxy and voting materials for special general meetings, incorporation of selected 6-K disclosures into Form S-8 and Form F-3 registration statements, and references to the company’s ordinary shares. These documents describe governance procedures, capital-market registration matters, listing-status communications and development updates for Galmed’s clinical-stage biopharmaceutical business.
Galmed Pharmaceuticals Ltd. (GLMD) reported that it has rebranded as EoCene Ltd. and will change its Nasdaq ticker to EOCN, with the name and symbol changes expected to become effective on the Nasdaq Capital Market on September 10, 2026. The company states that the new identity reflects its transition from a liver-focused, pre‑revenue biotech into a diversified, GI‑focused medtech and biopharmaceutical platform centered on its Colospan subsidiary and the CG‑100 colorectal device, alongside its Aramchol therapeutic programs.
The company also disclosed that it has terminated its Standby Equity Purchase Agreement with Yorkville, which had provided an equity line of up to $20 million; as of termination, it had raised approximately $7.3 million through the issuance of 437,947 ordinary shares. As of June 30, 2026, Galmed reported $11 million in cash, cash equivalents, short‑term deposits and marketable debt securities. The company notes it has regained compliance with Nasdaq’s minimum bid price requirement, so its ordinary shares will continue to be listed and traded on the Nasdaq Capital Market under the new ticker. Shareholders approved all proposals at the September 3, 2026 annual general meeting, including amended and restated Articles of Association that, among other things, fix authorized capital at 112,500,000 no‑par ordinary shares and set detailed rules for governance, board classification, meetings, and indemnification.
Galmed Pharmaceuticals Ltd. (GLMD) reports that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company’s ordinary shares will continue to be listed and traded on The Nasdaq Stock Market after maintaining a closing bid price of at least $1.00 per share for 10 consecutive trading days.
Galmed had previously been notified on January 29, 2026 of a bid-price deficiency and went through an initial and an additional 180-day compliance period before achieving the required trading performance between August 20, 2026 and September 2, 2026. This matter is now closed, and the report is incorporated by reference into the company’s effective Form S-8 and Form F-3 registration statements.
Galmed Pharmaceuticals Ltd. (GLMD) reports that it held its Annual General Meeting of Shareholders on September 3, 2026. Shareholders approved all proposals presented at the meeting with the requisite majority under the Israeli Companies Law, 5759-1999. The report is also incorporated by reference into Galmed’s effective Form S-8 and Form F-3 registration statements.
Galmed Pharmaceuticals Ltd. (GLMD) filed Post-Effective Amendment No. 4 to its Form F-1 to update a resale registration tied to a Standby Equity Purchase Agreement with YA II PN, LTD. The amendment covers the resale of up to 673,678 ordinary shares that may be issued to YA as "Advance Shares" under a $20.0 million equity commitment running for 36 months from August 30, 2024. Galmed has already issued 437,947 Advance Shares to YA for approximately $7.3 million, plus 3,946 commitment shares as consideration for the facility. As of September 1, 2026, Galmed had 1,068,234 shares outstanding; if all 673,678 registered shares are issued, they would represent about 39.6% of outstanding shares, highlighting potential dilution. Pricing for future sales to YA will be at 97% of the lowest of three daily VWAPs over a three-day period, subject to a 4.99% beneficial ownership cap. Galmed completed the $3.3 million cash acquisition of Colospan Ltd. in June 2026, with up to $2.0 million additional earnout tied to future net revenue, and effected a 1‑for‑8 reverse share split on August 19, 2026. The company notes Nasdaq listing risk, including that its market value of listed securities was about $4.2 million, below a proposed $5.0 million continued-listing threshold that remains stayed.
Galmed Pharmaceuticals Ltd. (GLMD) reports unaudited results for the three and six months ended June 30, 2026 and details the completed acquisition of Colospan Ltd., a colorectal surgical device company. The Colospan deal totaled $4.9 million in consideration, including $3.3 million in cash and $1.6 million of contingent consideration, plus potential earnouts of up to $2.0 million tied to future net sales.
Galmed recorded a net loss of $2.7 million for the quarter and $4.7 million for the first half of 2026, with research and development expenses up about 82% year over year to $3.1 million for the six‑month period. Cash, short-term deposits, restricted cash and marketable debt securities totaled about $11.4 million as of June 30, 2026, down from roughly $18.3 million at December 31, 2025, mainly due to operating cash burn and the cash component of the Colospan acquisition.
Management believes the current cash position supports operations for more than 12 months from issuance of these statements but states that substantial additional capital will be needed to advance Aramchol, Amilo‑5MER and Colospan’s programs. The company also discloses a 1‑for‑8 reverse share split effective August 20, 2026 and highlights potential Nasdaq delisting risk tied to a proposed $5.0 million Market Value of Listed Securities requirement, noting its MVLS was about $4.2 million on September 1, 2026.
Galmed Pharmaceuticals Ltd. (GLMD) convened its Annual General Meeting of Shareholders on September 2, 2026, but adjourned it for one day due to lack of quorum. The meeting will be reconvened on September 3, 2026 at 4:00 p.m. Israel time at Meitar Law Offices in Ramat Gan.
The company states that this report is incorporated by reference into its registration statements on Form S-8 and Form F-3. The report is signed by President and Chief Executive Officer Allen Baharaff.
Galmed Pharmaceuticals Ltd. (GLMD) filed an amended Form 6-K to reschedule its annual general meeting to September 2, 2026 and to furnish the full amended compensation policy for directors and executive officers, which now governs future pay, bonuses, equity awards and change‑of‑control terms.
Shareholders will vote on five proposals: re‑electing Dr. David Sidransky and Mr. Amir Poshinski as Class III directors through 2029; amending the articles to eliminate par value and change the company name to “Eocene Ltd.”; approving the updated compensation policy; increasing annual director cash fees from $40,000 to $48,000 (expert external director from $50,000 to $60,000); and reappointing Brightman Almagor Zohar & Co. (Deloitte Israel) as auditor for 2026.
The policy introduces higher potential CEO cash bonus caps (up to 275% of base salary including special bonuses), revised equity grant limits (up to 200% of base salary or 0.5% of market value per year), detailed change‑of‑control protections, and larger D&O insurance limits. As of July 22, 2026, 8,262,953 ordinary shares were outstanding, each with one vote.
Galmed Pharmaceuticals Ltd. (GLMD), through its wholly owned subsidiary Colospan Ltd., reported successful first-in-human proof-of-concept clinical study results for a novel intraoperative colon tissue quality assessment platform. Colospan completed a feasibility study in 32 colorectal cancer patients undergoing elective colorectal surgery at three leading Israeli medical centers.
The study showed that quantitative measurement of colon tissue compliance using a novel ex-vivo methodology is technically feasible, with successful measurements obtained in all 32 patients and no measurement failures or procedure-related technical issues. These findings provide the initial clinical foundation for continued development of an intraoperative device intended to give surgeons objective, real-time, quantitative information on colon tissue quality, potentially supporting surgical decision-making and risk assessment for complications such as Low Anterior Resection Syndrome.
The platform is described as Colospan’s second technology, expanding beyond its lead product CG-100, an intraluminal bypass device that has FDA Breakthrough Device Designation, CE marking under EU Medical Device Regulation, and an FDA-approved IDE for investigational use in the United States. Galmed highlights this as part of a broader strategy to build a diversified portfolio in colorectal surgery and gastrointestinal and oncological innovation, alongside its flagship molecule Aramchol.
Galmed Pharmaceuticals Ltd. (GLMD), a clinical-stage biopharmaceutical company, reported new pre-clinical data on a combination of its SCD1 inhibitor Aramchol with Xtandi® (enzalutamide) in prostate cancer models. In a VCaP prostate cancer cell line, the combination produced a 3–4-fold increase in cell death compared with enzalutamide alone, with the interaction strengthening over time.
Galmed links this effect to blocking tumor lipid desaturation pathways that support resistance to standard-of-care anti-androgen therapy. The company highlights that Xtandi recorded $8 billion and $6 billion in global sales in 2024 and 2025 and faces main patent expirations in 2026 (Europe) and 2027 (U.S.), with a U.S. price cut scheduled for 2027.
Galmed has submitted a patent application covering the Aramchol–enzalutamide combination and plans to initiate discussions with potential partners as a possible lifecycle management strategy around Xtandi and future generic competition. In parallel, Galmed continues to advance Aramchol and its CG-100 colorectal surgery device for gastrointestinal, cardiometabolic and oncology indications.